FDA Fast Tracks Muscular Dystrophy Drug backed by Woodford – Labiotech.eu (blog)

Posted: Published on May 31st, 2017

This post was added by Dr. Richardson

The FDA has handed out a Fast Track Designation to AMO Pharma for its key asset AMO-02 to treat congenital myotonic dystrophy.

The British-American biotech hybrid AMO Pharma is advancing asmall pipeline of drugs for rare genetic disorders. The biotech, which is backed by famous UK Investor Neil Woodford, is currently pushing its lead candidate AMO-02 through Phase II as the first-ever treatment for myotonic dystrophy. Now, AMO will also be backed by regulatory agencies, after the FDA today announced that it has granted Fast Track Designation for AMO-02.

The Fast Track Designation paves the way for an accelerated approval process for AMOs lead drug and includes a priority review that clips four months off the FDAs decision process. This is great news for patients suffering from the disease, which represents the most common form of muscular dystrophy, and for which there is currently no approved therapy available.

AMO-02 tries to tackle the most severe form of myogenic dystrophy known as congenital DM1. The drug works by inhibiting theglycogen synthase kinase 3 beta (GSK3), which is extra active in patients with DM1 as well as duchenne muscular dystrophy. So far, theinhibitor was able to demonstrate pre-clinical efficacy in transgenic models.

AMOs Pipeline.

Our ongoing PhaseII clinical trial for AMO-02 in the UK is the first sponsor-led clinical study in the treatment of congenital myotonic dystrophy and represents a historic milestone in research and a new era of hope for patients and their families affected by this serious condition,commented Michael Snape, CEO of AMO Pharma.

The company only has one other preclinical candidate in its pipeline, which is being developed for the treatment of Fragile X syndrome. Yet, competition-wise AMO Pharma seems to have good chances on the market.

Since US-based IonisPharmaceuticals, which was partnered up with Biogen, failed Phase I/II trials with its DM1 drug earlier this year, there are not many biotechs left in the space. Moreover, afterBioMarins recent Phase III failure with its ProSensa buy-out for the treatment for Duchenne, AMO could be all set to tackle this disease as well. Its maybe not surprising that the early-stage company was able to rake in an impressive 25M from Woodford.

Images via shutterstock.com / Choksawatdikorn andamo-pharma.com

Go here to read the rest:
FDA Fast Tracks Muscular Dystrophy Drug backed by Woodford - Labiotech.eu (blog)

Related Posts
This entry was posted in Muscular Dystrophy Treatment. Bookmark the permalink.

Comments are closed.